Holen Sie sich die Stockscreener-App
108.30
3.05%
-3.41
Vorhandelsmarkt:
109.18
0.88
+0.81%
Schlusskurs vom Vortag:
$111.71
Offen:
$110.28
24-Stunden-Volumen:
501.51K
Relative Volume:
0.67
Marktkapitalisierung:
$5.01B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.78M
KGV:
-40.41
EPS:
-2.68
Netto-Cashflow:
$-53.91M
1W Leistung:
+3.00%
1M Leistung:
-2.73%
6M Leistung:
+102.13%
1J Leistung:
+1,048%
1-Tages-Spanne:
$107.10
$112.81
1-Wochen-Bereich:
$104.45
$113.41
52-Wochen-Spanne:
$7.575
$120.31
Celcuity Inc Stock (CELC) Company Profile
Firmenname
Celcuity Inc
Sektor
Branche
Telefon
763-392-0767
Adresse
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
108.30 | 5.17B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-09-22 | Eingeleitet | Guggenheim | Buy |
| 2025-07-01 | Fortgesetzt | Stifel | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-02-22 | Eingeleitet | Stifel | Buy |
| 2023-12-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-09-07 | Eingeleitet | Jefferies | Buy |
| 2021-07-29 | Eingeleitet | Cowen | Outperform |
| 2021-07-27 | Eingeleitet | Needham | Buy |
| 2021-01-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-11 | Fortgesetzt | Craig Hallum | Buy |
| 2018-11-20 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Celcuity Inc Aktie (CELC) Neueste Nachrichten
A Look At Celcuity (CELC) Valuation After Charles Romp Joins The Board And Gedatolisib Progress - simplywall.st
Celcuity To Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph
Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise - Yahoo Finance
Bull Run: Should I set a stop loss on Celcuity IncJuly 2025 Opening Moves & Verified Swing Trading Watchlists - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (CELC) Movement - Stock Traders Daily
Is Celcuity’s (CELC) New Board Appointment a Turning Point for Its Commercial Strategy? - simplywall.st
Soleus Adds a Significant Number of Celcuity Shares - AOL.com
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - Yahoo Finance
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position - The Motley Fool
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuit - GuruFocus
Avoro Capital Advisors LLC Acquires Significant Stake in Celcuity Inc - GuruFocus
Celcuity Inc. (CELC) Stock Analysis: Biotechnology Innovator’s 9.29% Upside Captures Investor Attention - DirectorsTalk Interviews
Celcuity, Inc. (NASDAQ:CELC) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Decliners Report: How does Celcuity Inc correlate with Nasdaq2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn
What Celcuity (CELC)'s Board Addition of Veteran Oncology Executive Means For Shareholders - Yahoo Finance
Commit To Purchase Celcuity At $45, Earn 17.8% Using Options - Nasdaq
Has Celcuity (CELC) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Soleus Capital Increases Stake in Celcuity - Intellectia AI
Is Celcuity’s New Oncology Commercial Leader Appointment Reshaping the Investment Case for CELC? - simplywall.st
Celcuity Adds Veteran Director to Strengthen Oncology Strategy - TipRanks
Ex-Seagen oncology exec joins Celcuity board for breast cancer drug push - Stock Titan
Discipline and Rules-Based Execution in CELC Response - Stock Traders Daily
Can Celcuity Inc. ride the EV waveJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - mfd.ru
Celcuity Appoints Charles Romp to its Board of Directors - National Today
Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference - MarketBeat
Celcuity at Guggenheim Summit: Biotech Innovations Unveiled By Investing.com - Investing.com Canada
CELC: Gedatolisib nears approval with strong efficacy, broad utility, and major commercial potential - TradingView
Candriam S.C.A. Increases Holdings in Celcuity, Inc. $CELC - MarketBeat
Inflation Data: Does Celcuity Inc align with a passive investing strategyJuly 2025 Pullbacks & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Published on: 2026-02-08 07:23:47 - baoquankhu1.vn
Director Sells 20,000 Celcuity Shares for $2.4 Million Following 933% Share Price Jump - The Globe and Mail
Wall Street Recap: Is Celcuity Inc stock a smart retirement pickGold Moves & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Profit Review: Can Celcuity Inc ride the EV wave2025 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
Assessing Celcuity (CELC) Valuation After Recent Share Price Momentum And DCF Upside Estimate - Yahoo Finance
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst By Investing.com - Investing.com South Africa
Wolfe Research recommends buying Celcuity stock on weakness related to external catalyst - Investing.com Nigeria
Biotech Stocks To ResearchFebruary 4th - MarketBeat
Celcuity to Present at Upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Wealth Enhancement Advisory Services LLC Sells 10,476 Shares of Celcuity, Inc. $CELC - MarketBeat
Celcuity (CELC) Draws Investor Attention as Precision Oncology Strategy Advances - Insider Monkey
Jobs Data: Whats the beta of Celcuity Inc stockTrade Entry Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
Behavioral Patterns of CELC and Institutional Flows - Stock Traders Daily
Atle Fund Management AB Takes $1.84 Million Position in Celcuity, Inc. $CELC - MarketBeat
Celcuity granted FDA priority review for breast cancer therapy - MSN
Celcuity prices $248.7M debt, stock offerings - MSN
Celcuity Inc. (CELC) Stock Analysis: Navigating High Potential in Biotechnology with a $5.19 Billion Market Cap - DirectorsTalk Interviews
Assessing Celcuity (CELC) Valuation After FDA Priority Review Milestone For Gedatolisib - Sahm
Celcuity (NASDAQ:CELC) Director Sells $2,400,600.00 in Stock - MarketBeat
Finanzdaten der Celcuity Inc-Aktie (CELC)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):